In February, we welcomed our local news station for an insightful discussion on the recent NIH funding cuts and their potential impact on the scientific community.
Despite uncertainties, Intact Genomics remains committed to supporting research and pushing innovation forward. Our team is dedicated to making a difference and we are grateful for the opportunity to share our perspective.
We are thrilled to announce that Intact Genomics has been selected by the prestigious NIH SEED Company Showcase Program to participate in the Redefining Early Stage Investments (RESI) Conference 2025.
The Redefining Early Stage Investments (RESI) Conference 2025 is an important event for the life sciences sector, focusing on connecting early-stage life science companies with investors and strategic partners. The conference will take place on January 14, 2025, at the San Francisco Marriott Marquis, featuring in-person networking opportunities, followed by virtual partnering sessions from January 15-16. This event is part of the broader J.P. Morgan (JPM) Healthcare Week 2025. This week-long event is one of the largest gatherings of global healthcare leaders, including executives, investors, and innovators.
This recognition highlights Intact Genomics’ innovative work in molecular biology, drug discovery and diagnostics. The NIH SEED program supports companies whose track records demonstrate high-potential, and we are honored to be among those chosen to present our breakthroughs to a global audience of investors, industry leaders, and key stakeholders.
At the RESI Conference, Jennifer Gormley, VP of Business Development, and Dr. Chengcang Charles Wu, CEO of Intact Genomics will pitch IG®’s unique technologies including Direct Capture of Large DNA Fragments and Fungal Artificial Chromosome (FAC). We are proud to represent Intact Genomics on this important stage and look forward to engaging with potential investors and building strategic partnerships to accelerate our mission of advancing cutting-edge solutions that address critical challenges in healthcare and life sciences.
Stay tuned for updates as we gear up for this exciting event!
November 25, 2024 – Intact Genomics (IG®), a leading molecular biology reagent company, is proud to announce the launch of three new cutting-edge products tailored to enhance Recombinase Polymerase Amplification (RPA) technology. These new additions mark a significant step forward in delivering reliable, efficient, and user-friendly solutions for rapid nucleic acid detection. All IG RPA-related kits and enzymes can be in custom formats, including high concentrations, and they support lyophilization applications.
The three products include:
“These products exemplify our commitment to innovation and meeting the needs of our customers, ” said Charles Wu, CEO of Intact Genomics. “RPA technology has become a cornerstone in molecular diagnostics and genome research. With investment in new equipment and improvement in productivity, we also can offer more affordable high-quality products now. These new offerings aim to empower scientists with the tools they need for faster and more reliable results at lower costs.”
The launch of these products aligns with Intact Genomics’ mission to advance molecular biology solutions and underscores its role as a trusted partner in the scientific community. For more information about these products, or contact IG team at [email protected].
[St. Louis, September 3, 2024] – Intact Genomics, a pioneering molecular biology reagent company that provides first-class products and services for DNA/RNA isothermal amplification for disease diagnostics, simplified molecular cloning and transformation, gene-editing, and large DNA fragment cloning, is pleased to announce that BioQuote has been appointed as its exclusive distributor in the United Kingdom.
Established in 1988, BioQuote Limited is a fast-growing biotech company that is focused on the supply of innovative, quality-branded bioproducts to the bioscience industry. BioQuote will now exclusively distribute IG’s range of high-quality molecular biology reagents across the UK. The partnership combines Intact Genomics’ superior product portfolio with BioQuote’s extensive distribution network and market expertise.
“We are delighted to partner with BioQuote, whose commitment to excellence aligns perfectly with our own values,” said Rosa Ye, COO at Intact Genomics. “This collaboration will enhance our ability to serve researchers and laboratories in the UK, ensuring they have access to the advanced reagents they need to drive scientific discovery and innovation.”
This strategic partnership marks a new milestone in Intact Genomics’ ongoing efforts to expand its international presence and provide cutting-edge reagents and expert solutions to the life science research community in the United Kingdom.
Our CEO, Dr. Chengcang Charles Wu, attended the 16th annual Next Generation Dx Summit (https://www.nextgenerationdx.com) at the Capital Hilton in Washington D.C. where he had a post presentation and networked with other professionals and researchers to discuss important topics surrounding diagnostic advancements. Intact Genomics is a key player and contributor to novel diagnostic technology development, and we reviewed the innovative products and technologies this event featured.
At the SIVB World Congress, Intact Genomics proudly showcased our new and existing products to hundreds of event attendees from around the world. Our Sales Director, Matthew Jones, Business Development Director, Jennifer Gormley, and CEO, Dr. Chengcang Charles Wu, were able to connect with other biotechnology researchers and professionals to discuss collaboration opportunities. We pride ourselves in our ability to innovate and grow as in vitro biology research continues to evolve. Intact Genomics provides a range of superior quality products and services including Recombinase Polymerase Amplification (RPA) optimization enzymes, custom competent cells, DirectPlate® competent cells, and the Quick10™ cloning kit.
Intact Genomics (IG®) scientists and collaborators published 3 papers in peer-reviewed journals recently. For further details, click the links below or contact us for inquiries.
“Activation of cryptic biosynthetic gene clusters by fungal artificial chromosomes to produce novel secondary metabolites”. AIMS Microbiol, 2023; 9(4): 757–779. Published online 2023 Dec 18
“The Identification and Heterologous Expression of the Biosynthetic Gene Cluster Encoding the Antibiotic and Anticancer Agent Marinomycin”. Biomolecules, January 16, 2024
“Terpenoid balance in Aspergillus nidulans unveiled byheterologous squalene synthase expression“. ScienceAdvances, February 21, 2024
These papers represent the culmination of relentless dedication, pioneering spirit, and collaborative efforts within our research community. We extend our heartfelt gratitude to all contributors and eagerly anticipate the transformative impact of these discoveries on science and society.
Stay tuned for more exciting developments from IG scientists as we continue to push the boundaries of life sciences exploration.
On November 30 and Dec 1, 2023, Intact Genomics (IG) had the pleasure of hosting high school students from St. Louis County Parkway schools who participate in Spark and Center for Advanced Professional Studies (CAPS) programs.
Jennifer Gormley, Director of Business Development introduced our innovative products and services used by many scientists around the world, Dr. David Brent Halling, Director of Product Development at Intact Genomics, showed students how cutting-edge technology is developed at IG, and Dr. Chengcang Charles Wu, CEO & Co-founder of Intact Genomics, told a story about how he became a world-renowned scientist and dedicated entrepreneur from being a country boy born to a poor family and illiterate parents in a village of Anhui, China.
These bright students asked terrific questions showing they are eager to learn and participate in life sciences. Student Maura Korte said: “I learned a lot about proteins and how important they are in biotechnology. I feel like you usually only hear about DNA in biotechnology so it was fascinating to see that the field is so much bigger than that!” Hayden Steinkuehler said: “It was a very cool experience in seeing what we might want to do in the future.”
Spark! provides high school students with dynamic, immersion-based student learning experiences to ensure students can understand and respond to an ever-changing world. Center for Advanced Professional Studies (CAPS) programs are nationally recognized, innovative high school programs. CAPS is an example of how business, community and public education can partner to produce personalized learning experiences that educate the workforce of tomorrow, especially in high-skill, high-demand jobs. Intact Genomics is proud to do our part in inspiring talented individuals towards careers in STEM to improve the world.
St. Louis, MO. (August 7, 2023) – Intact Genomics (IG®), a leading provider of cutting-edge molecular biology products and services, is proud to announce that it has been granted the prestigious ISO 13485:2016 certification for the design, development, manufacture and distribution of molecular biology products and services, in standard or custom format for both industries and academic institutes.
ISO 13485 is an internationally recognized standard specifically tailored for medical device manufacturers and companies involved in the design, development, production, and distribution of in vitro diagnostic (IVD) kits and reagents. The certification process involves a rigorous evaluation of a company’s quality management system, ensuring that it complies with the stringent requirements set forth by the ISO 13845 standards.
“Receiving the ISO 13485 certification is a significant milestone for Intact Genomics, ” said Dr. Chengcang Charles Wu, CEO of Intact Genomics. ” This milestone reflects the hard work and collective effort of our entire team to uphold the highest quality standards in our industry. With ISO 13485 certification, our customers can have even greater confidence in the reliability and performance of our molecular biology solutions.”
“Our team has worked tirelessly to implement and adhere to the standards set by ISO 13485,” said Dr. David Brent Halling, Leader of Protein Products Development and Laboratories Manager. “Intact Genomics’ certification to this standard proves and demonstrates to the international community that our products are made with strict adherence to traceability and quality control. This achievement reflects our unwavering commitment to delivering reliable and precise products and services for molecular biology research and diagnostics applications. It also showcases our dedication to meeting the needs and expectations of our valued customers and collaborators.”
The ISO 13485 certification further solidifies Intact Genomics’ position as a trusted partner in the molecular biology industry. The company remains committed to ongoing quality improvement initiatives, ensuring that its products and services continue to meet the evolving needs of the scientific community.
About Intact Genomics, Inc.
Established in 2013, Intact Genomics is a worldwide leader in large DNA fragment cloning and metagenomics technologies. The company continuously focuses on genomic technology innovation by applying large DNA fragment cloning related proprietary technologies in metagenomic research to develop new solutions for natural product-enzyme discovery, agricultural research, and environmental protection. Intact Genomics also provides high-quality life science products and services to help scientists explore the genome structure and function of microorganisms, plants, and animal species. We are proud to provide products and services for more than 2,000 laboratories worldwide.
Intact Genomics® and IG® are registered trademarks of Intact Genomics, Inc.
Media Contact:
Andrew Robertson
Vice President of Sales & Marketing
Intact Genomics
11840 Westline Industrial Drive, Suite 120
St. Louis, MO 63146
Email: [email protected]
Phone: 314-942-3655 ext. 102
Intact Genomics won first place in the USA from Wazoku Crowd Challenge 12091216978 for our scientist’s submission to Corteva Agriscience™ Open Innovation opportunity on Novel solutions for fungal nucleic acid extraction in May 2023. Intact Genomics is the worldwide leader in large DNA fragment extraction, cloning & metagenomic technologies. Our patented Fungal Artificial Chromosome (FAC) technology can capture large DNA fragments up to 300 kb and shuttle them into advanced or engineered fungal hosts for heterologous expression.